Sei Investments CO Hutchmed (China) LTD Transaction History

Sei Investments CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$16.25 - $20.23 $176,670 - $219,940	10,872 New	10,872 $196,000
Q2 2022 Aug 15, 2022	SELL	$8.59 - $20.77 $1.43 Million - $3.47 Million	-166,930 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$15.52 - $35.65 $195,489 - $449,047	12,596 Added 8.16%	166,930 $3.16 Million
Q4 2021 Feb 14, 2022	BUY	$28.89 - $35.33 $1.67 Million - $2.04 Million	57,786 Added 59.85%	154,334 $5.41 Million
Q3 2021 Nov 12, 2021	BUY	$35.66 - $42.94 $582,541 - $701,467	16,336 Added 20.37%	96,548 $3.54 Million
Q2 2021 Aug 06, 2021	BUY	$23.7 - $39.27 $580,507 - $961,879	24,494 Added 43.96%	80,212 $3.15 Million
Q1 2021 May 12, 2021	SELL	$27.01 - $36.8 $64,742 - $88,209	-2,397 Reduced 4.12%	55,718 $1.57 Million
Q4 2020 Feb 08, 2021	BUY	$27.51 - $34.36 $279,776 - $349,441	10,170 Added 21.21%	58,115 $1.86 Million
Q3 2020 Nov 06, 2020	BUY	$25.8 - $34.61 $1.24 Million - $1.66 Million	47,945 New	47,945 $1.55 Million

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.